Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells von Teh, Jessica L. F., Shah, Raj, La Cava, Stephanie, Dolfi, Sonia C., Mehta, Madhura S., Kongara, Sameera, Price, Sandy, Ganesan, Shridar, Reuhl, Kenneth R., Hirshfield, Kim M., Karantza, Vassiliki, Chen, Suzie

Volltext

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment von Teh, Jessica L F, Aplin, Andrew E

Volltext

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma von Chua, Vivian, Orloff, Marlana, Teh, Jessica LF, Sugase, Takahito, Liao, Connie, Purwin, Timothy J, Lam, Bao Q, Terai, Mizue, Ambrosini, Grazia, Carvajal, Richard D, Schwartz, Gary, Sato, Takami, Aplin, Andrew E

Volltext

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition von Hofmann, Marco H, Gmachl, Michael, Ramharter, Juergen, Savarese, Fabio, Gerlach, Daniel, Marszalek, Joseph R, Sanderson, Michael P, Kessler, Dirk, Trapani, Francesca, Arnhof, Heribert, Rumpel, Klaus, Botesteanu, Dana-Adriana, Ettmayer, Peter, Gerstberger, Thomas, Kofink, Christiane, Wunberg, Tobias, Zoephel, Andreas, Fu, Szu-Chin, Teh, Jessica L, Böttcher, Jark, Pototschnig, Nikolai, Schachinger, Franziska, Schipany, Katharina, Lieb, Simone, Vellano, Christopher P, O'Connell, Jonathan C, Mendes, Rachel L, Moll, Jurgen, Petronczki, Mark, Heffernan, Timothy P, Pearson, Mark, McConnell, Darryl B, Kraut, Norbert

Volltext

Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition von Nguyen, Mai Q., Teh, Jessica L.F., Purwin, Timothy J., Chervoneva, Inna, Davies, Michael A., Nathanson, Katherine L., Cheng, Phil F., Levesque, Mitchell P., Dummer, Reinhard, Aplin, Andrew E.

Volltext

Playing the Melanoma Endgame von Teh, Jessica L F, Aplin, Andrew E

Volltext

Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma von Teh, Jessica L F, Purwin, Timothy J, Han, Anna, Chua, Vivian, Patel, Prem, Baqai, Usman, Liao, Connie, Bechtel, Nelisa, Sato, Takami, Davies, Michael A, Aguirre-Ghiso, Julio, Aplin, Andrew E

Volltext

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms von Teh, Jessica L F, Cheng, Phil F, Purwin, Timothy J, Nikbakht, Neda, Patel, Prem, Chervoneva, Inna, Ertel, Adam, Fortina, Paolo M, Kleiber, Ines, HooKim, Kim, Davies, Michael A, Kwong, Lawrence N, Levesque, Mitch P, Dummer, Reinhard, Aplin, Andrew E

Volltext

Glutamatergic signaling in cellular transformation von Teh, Jessica L. F., Chen, Suzie

Volltext

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma von Teh, Jessica L F, Purwin, Timothy J, Greenawalt, Evan J, Chervoneva, Inna, Goldberg, Allison, Davies, Michael A, Aplin, Andrew E

Volltext

Frizzled with age: an opportunity for 'gerontological medicine' von Teh, Jessica L. F.

Volltext

Activation of CD8 + T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors von Teh, Jessica L F, Erkes, Dan A, Cheng, Phil F, Tiago, Manoela, Wilski, Nicole A, Field, Conroy O, Chervoneva, Inna, Levesque, Mitch P, Xu, Xiaowei, Dummer, Reinhard, Aplin, Andrew E

Volltext

Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor von Teh, Jessica L. F., Shah, Raj, Shin, Seung-Shick, Wen, Yu, Mehnert, Janice M., Goydos, James, Chen, Suzie

Volltext

Abstract 3096: CDK4/6 as a therapeutic target in malignant melanoma von Teh, Jessica L., Aplin, Andrew

Volltext

Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma von Tiago, Manoela, Teh, Jessica L., Purwin, Timothy J., Cai, Weijia, Hollingworth, Connor, Lopez-Anton, Melisa, Aguirre-Ghiso, Julio A., Aplin, Andrew E.

Volltext

Abstract 5199: An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma von Teh, Jessica L., Purwin, Timothy, Greenawalt, Evan J., Chervoneva, Inna, Goldberg, Allison, Davies, Michael E., Aplin, Andrew

Volltext

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms von Teh, Jessica L F, Cheng, Phil F, Purwin, Timothy J, Nikbakht, Neda, Patel, Prem, Chervoneva, Inna, Ertel, Adam, Fortina, Paolo M, Kleiber, Ines, HooKim, Kim, Davies, Michael A, Kwong, Lawrence N, Levesque, Mitch P, Dummer, Reinhard, Aplin, Andrew E

Volltext

E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms von Teh, Jessica L F, Cheng, Phil F, Purwin, Timothy J, Nikbakht, Neda, Patel, Prem, Chervoneva, Inna, Ertel, Adam, Fortina, Paolo M, Kleiber, Ines, HooKim, Kim, Davies, Michael A, Kwong, Lawrence N, Levesque, Mitch P, Dummer, Reinhard, Aplin, Andrew E

Volltext

A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling von Romano, Gabriele, Chen, Pei-Ling, Song, Ping, McQuade, Jennifer L, Liang, Roger J, Liu, Mingguang, Roh, Whijae, Duose, Dzifa Y, Carapeto, Fernando C L, Li, Jun, Teh, Jessica L F, Aplin, Andrew E, Chen, Merry, Zhang, Jianhua, Lazar, Alexander J, Davies, Michael A, Futreal, P Andrew, Amaria, Rodabe N, Zhang, David Y, Wargo, Jennifer A, Kwong, Lawrence N

Volltext

Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma von Tiago, Manoela, Purwin, Timothy J., Fane, Mitchell E., Chhabra, Yash, Teh, Jessica L. F., Kadamb, Rama, Cai, Weijia, Chervoneva, Inna, Rosenbaum, Sheera, Chua, Vivian, Hacohen, Nir, Davies, Michael A., Villanieva, Jessie, Weeraratna, Ashani T., Capparelli, Claudia, Aguirre-Ghiso, Julio A., Aplin, Andrew E.

Volltext